Cambridge Cognition Holdings Plc · LSE:COG
Cambridge Cognition — FY2024 Earnings Presentation
15 slides from Cambridge Cognition's earnings presentation, 2025
Slide 1: Cambridge Cognition 2024 Final Results
2025 Cambridge Cognition 2024 Final Results Date
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, ITS TERRITORIES OR POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND TH
Slide 3: Agenda & Presenters
Agenda & Presenters 2024 Highlights Rob Baker 2024 Financial Performance Chief Operating Officer, acting Joint Managing Director About Cambridge Cognition: Product & operations 15 years • Market Opportunities • Amazon • Siemens • Our Go-to-market Approach • Science & Technology Foundations Outlook R
Slide 4: Quote on building a strong global brand with scalable technology
“Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health.” 4 | PRIVATE AND CONFIDENTIAL | © Cambridge Cognition 2025. All rights reserved. www.cambridgec
Slide 5: 2024 Highlights
2024 Highlights • Commercial team rebuilt with a revised strategy focused on large pharma and biotech, leading to £7.4m in new Sales Orders in 2024 – with £3.1m in Q4 2024 and £4.2m in Q1 2025. • Strengthened leadership with new Joint Acting Managing Directors, three new Non-Executive Directors, and
Slide 6: 2024 Financial Performance
2024 Financial Performance Income Statement Balance Sheet 2024 2023 2024 2023 Click to add £m £m £m £m copy Revenue 10.3 13.5 Assets Cost of sales (1.9) (2.7) Investments 1.8 0.2 Gross profit 8.4 10.8 Other non-current assets 6.9 7.9 Operating expense (10.0) (14.4) Total non-current assets 8.7 8.1 O
Slide 7: Sales >> Order Book >> Revenue
Sales >> Order Book >> Revenue Click to add 4,500 copy New Sales Orders £4.2M 4,000 £0.6M Change orders 3,500 £3.6M £3.1M 3,000 £0.5M 2,500 £2.3M £2.6M 2,000 £1.6M 1,500 £1.1M 1,000 £0.9M £0.4M £0.3M 500 £0.7M £0.7M £0.6M - Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 7 | PRIVATE AND CONFIDENTIAL | © Cam
Slide 8: Market Opportunities
Market Opportunities Clinical Trials Academic Research Healthcare Consumer • Digital & Voice Cognitive • Software as a Service (SaaS) • CANTAB Mobile (CE-Marked • Scope for partnerships, Assessments and FDA 510k medical device) licensing, and geographic • Collaborations expansion • Electronic Clinic
Slide 9: Our Go-to-Market Approach
Our Go-to-Market Approach New Sales Orders by Customer Profile Sales enablement 100% 1. Click to add 90% Brand awareness 80% 2. copy Lead generation campaigns supported with Inside Sales 70% 60% 3. Strengthened leadership , business development & bid management 50% 40% 4. Strategic account managemen
Slide 10: Science & Technology Foundations
Science & Technology Foundations Our Offering Our Evidence Our IP All in One Platform Widespread usage • Branded solutions, some over 20 • Breadth of offering with cognitive • Delivered over 500 clinical trials years assessments, eCOA & quality assurance • Nearly 100 cited primary / secondary • Mix
Slide 11: Outlook
Outlook Market Growth • New products and services expanding addressable market1 • CNS and trials growth forecast at >10% between 2025-20302,3 • Active CNS market with $54bn4 in acquisitions in the last 2 years Market Drivers • Aging population • Continued awareness and adoption of technology • Posit
Slide 12: Summary
Summary Reset business with profitable model • Transformed commercial operations with Tier-1 pharma focus and stronger execution • Cost base reduced - operational leverage now boosting profitability • Strong new business pipeline supports sustained revenue and cashflow growth Unique digital CNS Plat
Slide 13: Appendix
2025 Appendix Date
Slide 14: Momentum & Proof Points
Momentum & Proof Points Launch of in-house Rater CANTAB Use in Bristol Training, new service line to CANTAB used in one of the Contract Win - Phase 3 Myers Squib Research in support deployment of worlds largest ever brain Autoimmune study with Tier Schizophrenia Drug KARxt eCOA and AQUA studies, wit
Slide 15: Business Strategy
Business Strategy Strategy to deliver above-market growth with a focus on commercialisation Driving sales of Maturing our Maintain brand Driving efficiencies, Focusing on our existing products partnerships to position and ensuring continued people and winning a broaden reach and continue developing
Cambridge Cognition Holdings — FY2024 Earnings Presentation on 6ix